Severe Neurological Toxicity of Immune Checkpoint Inhibitors: Growing Spectrum
Ann Neurol 87:659-669, Dubey, D.,et al, 2020
Severe Neurological Toxicity of Immune Checkpoint Inhibitors: Growing Spectrum
Ann Neurol 87:659-669, Dubey, D.,et al, 2020
Inflammatory Demyelinating Polyneuropathy Versus Leptomeningeal Disease Following Ipilimumab
J Immunother Cancer 6:11, Cafuir, L.,et al, 2018
Neurological, Respiratory, Musculoskeletal, Cardiac and Ocular Side-Effects of Anti-PD-1 Therapy
Eur J Cancer 60:210-225, Zimmer, L.,et al, 2016
Neurological Immune-Related Adverse Events of Ipilimumab
Pract Neurol 13:278-280, Bot, I.,et al, 2013
Incidence and Outcome of Neurologic Immune-Related Adverse Events Associated with Immune Checkpoint Inhibitors in Patients with Melanoma
Neurol 101:e2472-e2482, Pepys,J.,et al, 2023
Myasthenia Gravis Following Dabrafenib and Trametinib for Metastatic Melanoma
Neurol 94:322-323, Zaloum, A.,et al, 2020
Pembrolizumab-Induced Myasthenia Gravis
Neurol 91:e1365-e1367, Algaeed, M.,et al, 2018
Dural Melanocytoma with Leptomeningeal Melanocytosis
Neurol 88:e70-e71, Schembri, M.,et al, 2017
Five Cases of Malignant Melanoma During Fingolimod Treatment in Dutch Patients with MS
Neurol 89:970-972, Killestein, J.,et al, 2017
Melanoma Complicating Treatment with Natalizumab for Multiple Sclerosis
NEJM 358:647-648, Mullen,J.T.,et al, 2008
Neurology and the Skin
JNNP 66:417-430, Hurko,O.&Provost,T.T., 1999
Chronic Inflammatory Demyelinating Polyneuropathy Associated with Malignant Melanoma
Neurol 46:822-824, Bird,S.J.,et al, 1996
Occurrence of Different Cancers in Patients with Parkinson's Disease
BMJ 310:1500-1501, Moller,H.,et al, 1995
Solitary Brainstem Metastasis
Neurol 28:562, Weiss,H.D.,et al, 1978
Malignant Melanoma and Central Nervous System Metastases, Incidence, Diagnosis, Treatment and Survival
Cancer 42:660-668, Amer,M.H.,et al, 1978
Infiltration of the Leptomeninges by Systemic Cancer:a Clinical & Pathologic Study
Arch Neurol 30:122, Olson,M.E.,et al, 1974